Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.

Swing & day trader
Tweets are my opinion only and not a recommendation to buy or sell any security.
I don't Have any subservice/ WhatsApp group /Telegram group!

HODOR

I have seen the stock market change people's lives! It can change yours too. Never Give Up! You may find my best stock ideas at: https://t.co/rqfRosoA4A

Marty Chargin

Small & mid-cap biotech | Special situations | Off-the-beaten-path ideas. Staunch believer in inefficient markets. Occasional beneficiary of them.

Dana Street Capital

USC Pharmacy Alumni, Full Time Investor. My tweets are a general reflection of my Investments and not a recommendation. Please do your own due diligence.

Abivax SA American Depositary Shares (ABVX) Stock Price, Analysis & Trade Signals